A 14q31.1-q32.11 deletion case: Genotype – Neurological Phenotype Correlations in 14q interstitial deletion syndrome

EUGENIA ROZA1, 2, 4#, IOANA STREAȚĂ3#, SIMONA ȘOȘOI3, FLORIN BURADA3, MARIA PUIU1, MIHAI IOANA3*, RALUCA IOANA TELEANU2,4

1Victor Babes University of Medicine and Pharmacy, Center of Genomic Medicine, Timisoara, Romania
2Department of Clinical Neurosciences, “Carol Davila” University of Medicine and Pharmacy, Bucharest, Romania
3University of Medicine and Pharmacy Craiova, Regional Centre for Medical Genetics Dolj – Clinical County Emergency Hospital Craiova, Romania
4“Victor Gomoiu” Children’s Hospital, Bucharest, Romania
#shared first authorship

Abstract

Interstitial deletions involving the long arm of chromosome 14 are rare conditions that associate facial dysmorphism, neurological features such as seizures, motor and cognitive delay with speech problems and autistic traits. We report on an 11-year-old girl of Tatar origin with an interstitial deletion involving region 14q31.1-q32.11. The affected region encompasses 46 genes, including 19 Mendelian genes. Epilepsy, motor and cognitive delay and speech problems are the main neurological features identified in our patient. Through the accurate mapping of the deleted region and comparison with previously reported patients, we aim to expand the knowledge regarding genotype-phenotype correlations in 14q interstitial deletion cases.

Keywords aCGH, 14q31.1-q32.11 deletion, NRXN3, epilepsy, EEG abnormalities.

To cite this article: ROZA E, STREAȚĂ I, ȘOȘOI S, BURADA F, PUIU M, IOANA M, TELEANU RI. A 14q31.1-q32.11 deletion case: Genotype – Neurological Phenotype Correlations in 14q interstitial deletion syndrome. Rom Biotechnol Lett. 2020; 25(3): 1677-1682. DOI: 10.25083/rbl/25.3/1677.1682

*Corresponding author: MIHAI IOANA, MD, PhD, Regional Centre for Medical Genetics Dolj, University of Medicine and Pharmacy Craiova, 1 Mai Blvd, No 66, Craiova, Romania
Postal code 200638, Tel. +40 726 697596
E-mail: mihai.ioana@geneticamedicala.ro mihaiioana_romania@yahoo.com
Introduction

Establishing the genetic aetiology of rare conditions has a significant impact on the quality of life of the patients and their families (VEARS et al, 2015 [1]; LINGEN et al, 2016 [2]; JATTOVICH GROSMAN et al, 2019 [3]; TEDRUS et al, 2020 [4]; GABRIEL et al, 2020 [5]). The development and improvement of classical or new genomic technologies over the last two decades (SCHUEFFER et al, 2011 [6]; MEFFORD, 2015 [7]; GONSALES et al, 2015 [8]; DOMINGUEZ-CARRAL et al, 2017 [9]; ORSINI et al, 2018 [10]; OATES et al, 2018 [11]) offered valuable and complex data to be used in the genetic counselling of cases with congenital anomalies, intellectual disability, autism spectrum disorders or epilepsy (OLSON et al, 2014 [12]; NICITA et al, 2015 [13]; LOVRÈĆIĆ et al, 2018 [14]; BĂNESCU 2019 [15]; COLLIVA et al, 2019 [16]; CAMPBELL et al, 2019 [17]). Chromosome 14 anomalies (both single-gene disorders and submicroscopic changes – deletion or duplication) are reported to be associated with: microcephaly, facial dysmorphic features, postnatal growth delay, pharaco-resistant seizures, autism, intellectual disability, cognitive delay with speech problems, vision loss and cerebral, heart, genitourinary or renal abnormalities (NICITA et al, 2015 [13]; MAURIN et al, 2006 [18]; CINGÖZ et al, 2011 [19]; TORGYEKES et al, 2011[20]; YOUNGS et al, 2012 [21]; ZOLLINO et al, 2012 [22]; OEHLSCHACHKWITZ et al, 2014 [23]; RIEDEL et al, 2014 [24]). Genetic counselling of such cases is a complex process (GODARD et al, 2004 [25]; ELSCA and DEPPIENNE 2015 [26]; GIUSSANI et al, 2020 [27]) and requires specific and complete data regarding prognosis and long-term management (KALSER and CROSS, 2018 [28]). Genetic diagnosis through high-resolution chromosomal analysis has improved the detection and molecular characterisation of microdeletions and microduplications (OLSON et al, 2014 [12]; MAGALHÃES et al, 2019 [29]; ELLIS et al, 2020 [30]) involving the long arm of chromosome 14. Accurate mapping of the affected regions, as well as the continuously updated online literature (MYERS & MEDFORD, 2015 [31]) and medical databases, have contributed to a better insight of the genotype-phenotype correlation (AVANZINI et al, 2018 [32]).

Here, we report on a patient with a de novo 14q31.1-q32.11 interstitial deletion. We have identified gene content, characterized deletion breakpoints and compared the clinical traits of our patient with those described in other reported cases with 14q interstitial losses of different sizes.

Clinical Report

Our patient was born at 38 weeks after an uneventful pregnancy, to healthy and non-consanguineous parents of Tatar origin. Her birth weight was 2850 g (25th centile), length was 49 cm (50th centile), and head circumference was 35 cm (75th centile). The Apgar score was 8. There was no family history of genetic conditions or birth defects. Her neonatal course was without significant events. Motor development was almost normal, with a mild lag in reaching the sitting position (7 months old) and walking independently (1 year and 3 months old), while language acquisition was delayed. The patient had learning difficulties, poor concentration and social interactions and an IQ of 62 (mild intellectual disability). The patient has always been at the high point of the weight for age curve, with normal stature.

At the age of 5, she presented unprovoked generalized seizures. The electroencephalogram (EEG) evaluation showed bilateral centro-temporal discharges of spike-wave complexes, with maximal amplitude in the right derivations. Routine biochemical analysis, hormonal profile and electrocardiogram yielded normal results. Cardiac and abdominal ultrasound findings were unremarkable. The first MRI exam identified unspecific periventricular signal anomalies. The second MRI performed at 10 years old revealed normal results. Seizures were relatively well managed for 7 months with Oxcarbazepine. Upon reoccurrence of the seizures, Nitrazepam was added but it was later replaced by Clonazepam due to side effects reported by parents (daytime drowsiness). The family reported increasing speaking difficulties, therefore Clonazepam was also withdrawn.

The most recent follow-up was at 11 years old. Neurological examination revealed balance problems and walking difficulties, with poor expressive and receptive language skills. Her language and social skills have been constantly improved with specific therapies (speech therapy and cognitive-behavioral therapy). Seizures are controlled by Oxcarbazepine and Levetiracetam. EEG showed very rare discharges, predominantly during sleep. Physical examination revealed an overweight child, with an androgy nous distribution of fatty tissue, particularly on the back of the neck and interscapulary, and with facial dysmorphism: upslanted palpebral fissures, round face, broad nasal bridge with mild hypertelorism (Figure 1). The patient has a hypopigmented macula on her torso, with a 5 cm diameter, present since birth. No other skin anomalies were identified. She has thoracic-cervical kyphosis and lumbar hyperlordosis.

Material and Methods

Blood was obtained from the patient after her parents had signed an informed consent. Genomic DNA was obtained from peripheral blood leukocytes, according to the protocol of the Wizard® Genomic DNA Purification Kit (Promega, Madison, WI, USA). Assessment of DNA
purity and concentration was performed through spectrophotometric measurements (Eppendorf Biophotometer).

High-resolution microarray (aCGH – comparative genomic hybridization) analysis was performed with Agilent SurePrint G3 CGH ISCA v2 8x60K microarrays, using commercially available male and female genomic DNA (Agilent Technologies, Human Reference DNA, Male and Female). All the procedures (restriction digestion, fluorescent labeling, purification of both patient and reference gDNA, hybridization, microarray wash and microarray scanning and analysis) were performed according to the manufacturer’s protocol (Agilent protocol – Version 7.4 August 2015). The NimbleGen MS 200 Microarray Scanner (Roche) acquired the array images. Agilent Feature extraction software was used to data extraction. Copy number data was analyzed with Agilent Cytogenomics 5.0 software (Agilent Technologies Inc., US).

**Results**

The aCGH analysis revealed a loss of genomic material corresponding to an interstitial deletion on the long arm of chromosome 14, 14q31.1-q32.11 region, of approximately 11.4 Mb: Arr[GRCh37] 14q31.1-q32.11 (79843213 – 91261373)x1 (ISCN 2016), (Figure 2). No karyotype was performed before to the child. The parental cytogenetic analysis was normal. The deleted region encompasses 46 RefSeq genes, of which 18 OMIM genes (NRXN3, DIO2, TSHR, GTF2A1, STON2, SEL1L, FLRT2, GALC, GPR65, KCNK10, SPATA7, PTPN21, ZC3H14, FOXN3, TDP1, KCNK13, PSMC1, CALM1).

![Figure 2.](image_url)

**Figure 2.** Chromosome 14 aCGH profile of the patient: detail of the 14q31.1-q32.11 region showing the deleted region of ~11.4 Mb.

| Patient | Deleted region | Deletion size | Seizures (age of onset; type) | EEG | MRI abnormalities |
|---------|----------------|---------------|-------------------------------|-----|-------------------|
| M, 11y – Kawamura et al, 1985 | 14q24.3-q32.1 | NR | Single afebrile seizure at 11 y | No epileptic anomalies | NR |
| M, 2y - Ono et al, 1999 | 14q24.3-q32.1 | NR | Simple FS at 13mo | Spikes in right O region | Frontal atrophy and delayed myelination |
| F, 5y - SchladeBartusiak et al, 2008 (HSC23984) | 14q24.3-q32.1 | 18.5 Mb | Focal, 2y | T-O anomalies | Normal |
| M, 2y Imo - Nicita et al, 2015 | 14q24.3-q31.1 | 5.5 Mb | 9 mo; Focal | Spikes in bilateral C regions | Corpus callosum hypoplasia; enlargement of fronto-temporal sub-arachnoids spaces |
| M – Patient 332786 – Decipher Database | 14q31.1 | 234.89 kb | seizures | NR | NR |
| M – Patient 332786 – Decipher Database | 14q31.1 | 91.25 kb | Infantile spasms, seizures | NR | NR |
| F, 13y – Vlaskamp et al, 2017, patient 337 | 14q31.1 | 319 kb | Focal seizures, 3.5y | Focal sharp waves (occ.) | Megacisterna magna |
| F, 8y – Vlaskamp et al, 2017, patient 969 | 14q24.3-q31.1 | 3.2 Mb | Focal SE, focal seizures (2 – 4/ month), 2 – 4 y | Normal | Normal |
| F, 11y - This report | 14q31.1-q32.11 | 11.4 Mb | unprovoked generalized seizures, 5y | bilateral centro-temporal discharges of spike-wave complexes, with maximal amplitude in the right derivations | Normal |
Discussion

In our study, we describe an 11-year-old girl presenting facial dysmorphism, seizures, epileptiform EEG activity, motor and cognitive delay with speech problems associated with a 14q interstitial deletion, extended from 14q31.1 to 14q32.11. In literature (both medical literature and online cytogenetics databases for unpublished patients – DECIPHER, ECARUCA, the Chromosome Anomaly Collection) there are 64 additional reported cases with interstitial 14q deletion syndrome which include our previously mentioned chromosomal region. 12 of these cases have inaccurate molecular characterization and a lack of breakpoints details, being reported before the era of high-resolution cytogenetics, when karyotype or FISH were the main diagnostic tools (TURLEAU et al., 1984 [33]; YAMAMOTO et al., 1986 [34]; GORSKI et al., 1990 [35]; KARNTITIS et al., 1992 [36]; Rivera et al., 1992 [37]; BYTH et al., 1995 [38]; ONO et al., 1999 [39]).

Patients with interstitial deletions of chromosome 14 usually share common clinical features like: facial dysmorphism, microcephaly, developmental and cognitive delay, seizures and speech problems (NICITA et al., 2015 [13]; CINGÖZ et al., 2011 [19]; TORGYEKES et al., 2011 [20]; OEHL JASCHKOWITZ et al., 2014 [23]; RIEGEL et al., 2014 [24]; PICCIONE et al., 2010 [40]; KAWAMURA et al., 1985 [41]). By comparing our patient with the previously published cases, common clinical features were found. Furthermore, the clinical picture of the patient herein reported showed important neurological impairment. She associated motor, cognitive and language delay with generalized seizures, abnormal EEG activity and mild intellectual disability. Thus, facial dysmorphism, motor, cognitive and language delay were described in almost all cases, while epilepsy and abnormal EEG activity were reported only in 8 patients with deletions located between 14q24.3 – q32.11 (NICITA et al., 2015 [13]; ONO et al., 1999 [39]; VLASKAMP et al., 2017 [42]; SCHLADEBARTUSIKA et al., 2008 [43]). Seizure types, onset age, localization of epileptiform activity on EEG and MRI results for our patient and ones previously published in literature are compared in Table 1. The deletion size of the affected region (14q24.3 – q32.11) in these nine patients ranges from approximately 91.25 kb to 18.5 Mb. Comparative analysis of the array CGH results available only for seven patients revealed that the region of deletion overlap contains the NRXN3 gene (MIM 600567), considered to be involved in the genetic etiology of bipolar pathology (HU et al., 2013 [44]) developmental delay (NOOR et al., 2014 [45]), intellectual disability, epilepsy and autism spectrum disorders (YUAN et al., 2018 [46]; FAHEEM et al., 2015 [47]). The NRXN3 gene encodes for neurexin III, a cell surface protein expressed in presynaptic terminals and required for synaptic cell adhesion and neurotransmission (NASEER et al., 2015 [48]; VAAAGS et al., 2012 [49]; KASEM et al., 2015 [50]; RUDENKO et al., 2019 [51]; DAI et al., 2019 [52]). Thus, the clinical findings described in our case, together with the other eight reported cases, reinforce the idea that haploinsufficiency of NRXN3 gene might cause epilepsy. Focusing on the entire gene content of the deleted region in our patient, aCGH revealed that the reported CNV contains other 13 MIM genes that could contribute and explain the entire clinical picture noticed in this case due to the role played by the encoded proteins.

Conclusions

In summary, our case shares a similar neurological picture characterized by seizures and EEG abnormalities with eight from the 64 previously reported cases, prompting us to sustain that NRXN3 might be a candidate gene for epilepsy. Confirmation of NRXN3 role in the etiology of epilepsy requires studies on larger cohorts and additional functional data. Furthermore, our case outlines that molecular assessment through aCGH can represent an important tool in the diagnostic work-up of epilepsy in children.

Abbreviations

- EEG – electroencephalogram
- MRI – magnetic resonance imaging
- aCGH – comparative genomic hybridization
- CNV – copy number variant

Conflict of Interest

The authors declare that they have no conflict of interests.

References

1. D.F. VEARS, K.L. DUNN, S.A. WAKE, I.E. SCHIEFFER. “It’s good to know”: Experiences of gene identification and result disclosure in familial epilepsies’, Epilepsy Research, vol. 112, pp. 64-71, May 2015, doi: 10.1016/j.yeber.2015.02.011.
2. M. LINGEN et al. ‘Obtaining a genetic diagnosis in a child with disability: impact on parental quality of life’, Clinical Genetics, vol. 89, no. 2, pp. 258-266, 2016.
3. I. JAITOVICH GROISMAN, T. HURLIMANN, B. GODARD. ‘Parents of a child with epilepsy: Views and expectations on receiving genetic results from Whole Genome Sequencing’, Epilepsy & Behavior, vol. 90, pp. 178-190, Jan. 2019, doi: 10.1016/j.ybeh.2018.11.020.
4. G.M.A. S. TEDRUS, J.M. LIMONGI, J.V.R. ZUNTINI. ‘Resilience, quality of life, and clinical aspects of patients with epilepsy’, Epilepsy & Behavior, vol. 103, p. 106398, Feb. 2020, doi: 10.1016/j.ybeh.2019.06.041.
5. D. GABRIEL et al. ‘Social impairment and stigma in genetic generalized epilepsies’, Epilepsy & Behavior, vol. 104, p. 106886, Mar. 2020, doi: 10.1016/j.ybeh.2019.106886.
6. I.E. SCHIEFFER. ‘Genetic Testing in Epilepsy: What Should you be Doing?: Genetic Testing in Epilepsy’,
A 14q31.1-q32.11 deletion case: Genotype – Neurological Phenotype Correlations in 14q interstitial deletion syndrome

Epilepsy Curr, vol. 11, no. 4, pp. 107-111, Jul. 2011, doi: 10.5698/1535-7511-11.4.107.

H.C. MEFFORD. ‘Clinical Genetic Testing in Epilepsy: Clinical Genetic Testing in Epilepsy’, Epilepsy Curr, vol. 15, no. 4, pp. 197-201, Jul. 2015, doi: 10.5698/1535-7511-15.4.197.

M.C. GONSALES, M.A. MONTENEGRO, C.V. SOLER, A.C. COAN, M.M. GUERRIERO, I. LOPES-CENDES. ‘Recent developments in the genetics of childhood epileptic encephalopathies: impact in clinical practice’, Arq. Neuro-Psiquiatr., vol. 73, no. 11, pp. 946-958, Nov. 2015, doi: 10.1590/0004-282X20150122.

J. DOMÍNGUEZ-CARRAL, J. LÓPEZ-PISÓN, A. MACAYA, M. BUENO CAMPAÑA, M.A. GARCÍA-PÉREZ, D. NATERA-DE BENTO. ‘Genetic testing among Spanish pediatric neurologists: Knowledge, attitudes and practices’, European Journal of Medical Genetics, vol. 60, no. 2, pp. 124-129, Feb. 2017, doi: 10.1016/j.ejmg.2016.11.007.

A. ORSINI, F. ZARA, P. STRIANO. ‘Recent advances in epilepsy genetics’, Neuroscience Letters, vol. 667, pp. 4-9, Feb. 2018, doi: 10.1016/j.neulet.2017.05.014.

S. OATES et al. ‘Incorporating epilepsy genetics into clinical practice: a 360° evaluation’, npj Genomic Medicine, vol. 3, no. 1, pp. 1-11, May 2018, doi: 10.1038/s41525-018-0052-9.

H. OLSON et al. ‘Copy number variation plays an important role in clinical epilepsy’, Annals of Neurology, vol. 75, no. 6, pp. 943-958, 2014, doi: 10.1002/ana.24178.

F. NICITA et al. ‘Neurological features of 14q24-q32 interstitial deletion: report of a new case’, Molecular cytogenetics, vol. 8, no. 1, p. 93, 2015.

L. LOVREČIĆ et al. ‘Diagnostic efficacy and new variants in isolated and complex autism spectrum disorder using molecular karyotyping’, Journal of applied genetics, vol. 59, no. 2, pp. 179-185, 2018.

C. BĂNESCU. ‘Do we really need genetic tests in current clinical practice?’, Revista Romana de Medicina de Laborator, vol. 27, no. 1, pp. 9-14, 2019.

C. COLLIVA, M. FERRARI, C. BENATTI, A. GUERRA, F. TASCEDDA, J.M.C. BLOM. ‘Executive functioning in children with epilepsy: Genes matter’, Epilepsy & Behavior, vol. 95, pp. 137-147, Jun. 2019, doi: 10.1016/j.ybeh.2019.02.019.

C. CAMPBELL, G. L. CAVALLERI, N. DELANTY. ‘Exploring the genetic overlap between psychiatric illness and epilepsy: A review’, Epilepsy & Behavior, vol. 102, p. 106669, Jan. 2020, doi: 10.1016/j.ybeh.2019.106669.

M.-L. MAURIN et al. ‘Terminal 14q32. 33 deletion: genotype–phenotype correlation’, American Journal of Medical Genetics Part A, vol. 140, no. 21, pp. 2324-2329, 2006.

S. CINGŐZ et al. ‘Interstitial deletion of 14q24. 3-q32. 2 in a male patient with plagiocephaly, BPES features, developmental delay, and congenital heart defects’, American Journal of Medical Genetics Part A, vol. 155, no. 1, pp. 203-206, 2011.

E. TORGYEKES et al. ‘The proximal chromosome 14q microdeletion syndrome: delineation of the phenotype using high resolution SNP oligonucleotide microarray analysis (SOMA) and review of the literature’, American Journal of Medical Genetics Part A, vol. 155, no. 8, pp. 1884-1896, 2011.

E.L. YOUNGS, M. DASOUKI, M.G. BUTLER. ‘14q32 deletion syndrome: a clinical report’, Clin Dysmorphol, vol. 21, no. 1, pp. 42-44, Jan. 2012, doi: 10.1097/MCD.0b013e328348d8d0.

M. ZOLLINO, E. PONZI, G. GOBBI, G. NERI. ‘The ring 14 syndrome’, European Journal of Medical Genetics, vol. 55, no. 5, pp. 374-380, May 2012, doi: 10.1016/j.ejmg.2012.03.009.

B. OEHL-JASCHKOWITZ et al. ‘Deletions in 14q24. 1q24. 3 are associated with congenital heart defects, brachydactyly, and mild intellectual disability’, American Journal of Medical Genetics Part A, vol. 164, no. 3, pp. 620-626, 2014.

M. RIEGEL, L.M. MOREIRA, L.D.E. SANTO, M.B.P. TORALLES, A. SCHINZEL, ‘Interstitial 14q24. 3 to q31. 3 deletion in a 6-year-old boy with a non-specific dysmorphic phenotype’, Molecular cytogenetics, vol. 7, no. 1, p. 77, 2014.

B. GODARD and G. CARDINAL. ‘Ethical implications in genetic counseling and family studies of the epilepsies’, Epilepsy & Behavior, vol. 5, no. 5, pp. 621-626, Oct. 2004, doi: 10.1016/j.ybeh.2004.06.016.

G. LESCA and C. DEPIENNE. ‘Epilepsy genetics: The ongoing revolution’, Revue Neurologique, vol. 171, no. 6, pp. 539-557, Jun. 2015, doi: 10.1016/j.neuro.2015.01.069.

G. GIUSSANI et al. ‘The management of epilepsy in clinical practice: Do the needs manifested by the patients correspond to the priorities of the caring physicians? Findings from the EPINEEDS Study’, Epilepsy & Behavior, vol. 102, p. 106641, Jan. 2020, doi: 10.1016/j.ybeh.2019.106641.

J. KALSER and J.H. CROSS. ‘New epilepsy treatment in children: upcoming strategies and rekindle to ancient times and concepts’, Paediatrics and Child Health, vol. 28, no. 10, pp. 474-479, Oct. 2018, doi: 10.1016/j.paed.2018.07.008.

P.H.M. MAGALHÃES, H.T. MORAES, M.C.P. ATHIE, R. SECOLIN, I. LOPES-CENDES. ‘New avenues in molecular genetics for the diagnosis and application of therapeutics to the epilepsies’, Epilepsy & Behavior, p. 106428, Aug. 2019, doi: 10.1016/j.ybeh.2019.07.029.
30. C.A. ELLIS, S. PETROVSKI, S.F. BERKOVIC. ‘Epilepsy genetics: clinical impacts and biological insights’, The Lancet Neurology, vol. 19, no. 1, pp. 93-100, Jan. 2020, doi: 10.1016/S1474-4422(19)30269-8.

31. C.T. MYERS and H.C. MEFFORD. ‘Advancing epilepsy genetics in the genomic era’, Genome Medicine, vol. 7, no. 1, p. 91, Aug. 2015, doi: 10.1186/s13073-015-0214-7.

32. G. AVANZINI, M. MANTEGAZZA, B. TERRAGNI, L. CANAFOGLI, P. SCALMANI, S. FRANCESCHETTI. ‘The impact of genetic and experimental studies on classification and therapy of the epilepsies’, Neuroscience Letters, vol. 667, pp. 17-26, Feb. 2018, doi: 10.1016/j.neulet.2017.05.026.

33. C. TURLEAU et al. ‘Two patients with interstitial del (14q), one with features of Holt-Oram syndrome. Exclusion mapping of PI (alpha-1-antitrypsin)’, in Annales de genetique, 1984, vol. 27, no. 4, pp. 237-240.

34. Y. YAMAMOTO, R. SAWA, N. OKAMOTO, A. MATSUI, M. YANAGISAWA, S. IKEMOTO. ‘Deletion 14q (q24. 3 to q32. 1) syndrome: significance of peculiar facial appearance in its diagnosis, and deletion mapping of (α 1-antitrypsin)’, Human genetics, vol. 74, no. 2, pp. 190-192, 1986.

35. J.L. GORSKI, W.R. UHLMANN, T.W. GLOVER. ‘A child with multiple congenital anomalies and karyotype 46, XY, del (14)(q31q32. 3): further delineation of chromosome 14 interstitial deletion syndrome’, American journal of medical genetics, vol. 37, no. 4, pp. 471-474, 1990.

36. S.A. KARNITIS, K. BURNS, K.W. SUDDUTH, W.L. GOLDEN, W.G. WILSON. ‘Deletion (14)(q24. 3q32. 1): evidence for a distinct clinical phenotype’, American journal of medical genetics, vol. 44, no. 2, pp. 153-157, 1992.

37. H. RIVERA, M.L. RAMIREZ-DUEÑAS, L.E. FIGUERA, R.M. GONZALEZ-MONTES, A.I. VASQUEZ. ‘Opposite imbalances of distal 14q in two unrelated patients.’, in Annales de genetique, 1992, vol. 35, no. 2, pp. 97-100.

38. B.C. BYTH, M.T. COSTA, I.E. TESHIMA, W.G. WILSON, N.P. CARTER, D.W. COX. ‘Molecular analysis of three patients with interstitial deletions of chromosome band 14q31.’, Journal of medical genetics, vol. 32, no. 7, pp. 564-567, 1995.

39. J. ONO et al. ‘Interstitial deletion of 14q, 46, XY, del (14)(q24. 3q32. 1) associated with status nonepileptic myoclonia and delayed myelination’, Journal of child neurology, vol. 14, no. 11, pp. 756-758, 1999.

40. M. PICCIONE et al. ‘Array CGH defined interstitial deletion on chromosome 14: a new case’, European journal of pediatrics, vol. 169, no. 7, pp. 845-851, 2010.

41. G. KAWAMURA, M. SUZUKI, T. SEGAWA, S. KOHNO. ‘A case of partial monosomy of 14q’, J Pediatr Pract, vol. 48, pp. 32-4, 1985.

42. D.R. VLASKAMP et al. ‘Copy number variation in a hospital-based cohort of children with epilepsy’, Epilepsia open, vol. 2, no. 2, pp. 244-254, 2017.

43. K. SCHLADE-BARTUSIACK, G. MACINTYRE, J. ZUNICH, D.W. COX. ‘A child with deletion (14)(q24. 3q32. 13) and auditory neuropathy’, American Journal of Medical Genetics Part A, vol. 146, no. 1, pp. 117-123, 2008.

44. X. HU et al. ‘Association study of NRXN3 polymorphisms with schizophrenia and risperidone-induced bodyweight gain in Chinese Han population’, Progress in Neuro-Psychopharmacology and Biological Psychiatry, vol. 43, pp. 197-202, Jun. 2013, doi: 10.1016/j.pnpbp.2012.12.007.

45. A. NOOR et al. ‘Copy number variant study of bipolar disorder in Canadian and UK populations implicates synaptic genes’, American Journal of Medical Genetics Part B: Neuropsychiatric Genetics, vol. 165, no. 4, pp. 303-313, 2014.

46. H. YUAN et al. ‘A rare exonic NRXN3 deletion segregating with neurodevelopmental and neuropsychiatric conditions in a three-generation Chinese family’, American Journal of Medical Genetics Part B: Neuropsychiatric Genetics, vol. 177, no. 6, pp. 589-595, 2018, doi: 10.1002/ajmg.b.32673.

47. M. FAHEEM et al. ‘Array-comparative genomic hybridization analysis of a cohort of Saudi patients with epilepsy’, CNS & Neurological Disorders-Drug Targets (Formerly Current Drug Targets-CNS & Neurological Disorders), vol. 14, no. 4, pp. 468-475, 2015.

48. M.I. NASEER et al. ‘Genome wide analysis of novel copy number variations duplications/deletions of different epileptic patients in Saudi Arabia’, BMC Genomics, vol. 16, no. 1, p. S10, Jan. 2015, doi: 10.1186/1471-2164-16-S1-S10.

49. A.K. VAAGS et al. ‘Rare deletions at the neurexin 3 locus in autism spectrum disorder’, The American Journal of Human Genetics, vol. 90, no. 1, pp. 133-141, 2012.

50. E. KASEM, T. KURIHARA, K. TABUCHI. ‘Neurexins and neuropsychiatric disorders’, Neuroscience Research, vol. 127, pp. 53-60, Feb. 2018, doi: 10.1016/j.neures.2017.10.012.

51. G. RUDENKO. ‘Neurexins – versatile molecular platforms in the synaptic cleft’, Current Opinion in Structural Biology, vol. 54, pp. 112-121, Feb. 2019, doi: 10.1016/j.sbi.2019.01.009.

52. J. DAI, J. AOTO and T.C. SÜDHOF. ‘Alternative Splicing of Presynaptic Neurexins Differentially Controls Postsynaptic NMDA and AMPA Receptor Responses’, Neuron, vol. 102, no. 5, pp. 993-1008.e5, Jun. 2019, doi: 10.1016/j.neuron.2019.03.032.